Transition Bio
Latest round
- Series A
Last raised
- Oct 2024
Total raised
- $44M
Investors
- 5
About Transition Bio
Based in the US, Transition Bio, Inc.Transition Bio, Inc. operates in the drug discovery sector, focusing on cutting-edge methodologies. The company was founded by Samuel Cohen and has undergone strategic developments to enhance its offerings. Its headquarters is based in Watertown, Massachusetts, US.Transition Bio specializes in an innovative drug discovery platform that integrates droplet microfluidics and advanced cellular imaging technologies to accelerate the identification of novel therapeutics at the molecular level. Their core offerings revolve around a unique end-to-end condensate drug discovery engine that leverages molecular insights to explore the interactions of chemical matter within biological condensate systems. This approach allows for comprehensive analysis and optimization of drug candidates, addressing critical challenges in treating complex diseases, particularly in oncology, neurodegenerative conditions, and inflammation.Transition Bio generates revenue primarily through strategic partnerships and collaborations with biopharmaceutical firms, research institutions, and other organizations involved in drug discovery. The company enters into agreements that typically involve access to their proprietary technology and data analytics platform, enabling clients to optimize their drug candidates more effectively. Transactions may be structured as collaborative research agreements or subscription-based access to their services, allowing clients to utilize the platform for ongoing projects.In October 2024, Transition Bio, Inc. Transition Bio aims to expand its reach by targeting new biopharmaceutical markets and enhancing its product offerings, thereby leveraging the latest technological advancements to cater to a broader client base.
Who invested in Transition Bio
5 investors across 3 rounds
See all investors in Transition Bio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Transition Bio
Who invested in Transition Bio?
Transition Bio has 5 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Transition Bio raised?
Transition Bio has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Transition Bio last raise money?
Transition Bio's most recent round on record is a Series A, in Oct 2024.
What does Transition Bio do?
Based in the US, Transition Bio, Inc.
Where is Transition Bio headquartered?
Transition Bio is headquartered in Watertown, US.
Which VCs invest in companies like Transition Bio?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Transition Bio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Transition Bio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.